ATLANTA, Sept. 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the upcoming UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City.
D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present Wednesday, September 24 at 2:30 p.m., Eastern Time.
CryoLife's live presentation may be accessed through its Web site, http://www.cryolife.com, on the Investor Relations page. An archived copy of the presentation will be available until October 25, 2008 on the same Web site.
Founded in 1984, CryoLife, Inc. is a leader in the processing and
distribution of implantable living human tissues for use in cardiac and
vascular surgeries throughout the U.S. and Canada. The Company recently
received FDA clearance for the CryoValve(R) SG pulmonary human heart valve,
processed using CryoLife's proprietary SynerGraft(R) Technology. The
Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to
sutures and staples for use in adult patients in open surgical repair of
large vessels. BioGlue is also CE marked in the European Community and
approved in Canada and Australia for use in soft tissue repair. CryoLife
distributes Hemostase MPH(R), a hemostatic agent, in much of the U.S. for
use in cardiac and vascular surgery and in the United Kingdom, Germany and
France for cardiac, vascular, and general surgery, subject to certain
exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless
Porcine Aortic Bioprosthesis, which is CE marked fo
|SOURCE CryoLife, Inc.|
Copyright©2008 PR Newswire.
All rights reserved